The current chair of the Federal Trade Commission will like to make a decision on the proposed merger of Walgreens and Rite Aid pharmacies before she leaves office-but the fate of the merger remains unclear.
The existing chair of the Federal Trade Commission (FTC) would like to make a decision on the proposed merger of Walgreens and Rite Aid pharmacies before she leaves office—but the fate of the merger remains unclear.
Walgreens agreed to buy Rite Aid for a total transaction that would exceed $17.2 billion, which would create a near monopoly for the chain by giving it control over 12,700 stores nationwide, and would position CVS in a distant second place with 7800 stores.
FTC scrutiny of the deal was definitely expected, with critics worried the merger would increase costs for consumers. To ease concerns, Walgreens announced in late 2016 that it would divest 865 Rite Aid stores to another smaller chain, Fred’s Inc, for $950 million, if the merger was approved. However, the FTC has not approved Fred’s for this deal, which currently owns fewer stores than what Walgreens is proposing to add to its plate. Would the 648-store chain be able to create a comprehensive plan for the new stores?
A bigger concern for the FTC is preserving market competition, and bringing Fred’s into the picture may not be sufficient to convince the FTC, reports Bloomberg. On an earnings call in early January, Stefano Pessina, CEO of Walgreens, told analysts that the company is striving to get the deal approved.
“We still have to complete our work with FTC and as we have seen these things can take some time, as the FTC are scrupulous in ensuring that they consider everything properly and fully,” Pessina said.
As the January 27 deadline—which has already seen an extension from the previous deadline of October 27, 2016—for closing the contract draws near, it’s not clear if FTC chairwoman Edith Ramirez has completed her review of the deal. In case it falls through, Rite Aid would receive $325 million or $650 million from Walgreens, “in certain circumstances.”
Ramirez has a track record of preventing market dominance—in the past, she prevented Staples from buying Office Depot and Sysco from buying US Foods.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Real-World Data Support Safety, Efficacy of Venetoclax for CLL
August 29th 2025A single-center study comparing patients with chronic lymphocytic leukemia receiving venetoclax as part of a clinical trial and patients receiving it in routine clinical practice showed very high complete response rates in both groups.
Read More
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen